Recent Advances of Vaccine Adjuvants for Infectious Diseases

Total Page:16

File Type:pdf, Size:1020Kb

Recent Advances of Vaccine Adjuvants for Infectious Diseases http://dx.doi.org/10.4110/in.2015.15.2.51 REVIEW ARTICLE pISSN 1598-2629 eISSN 2092-6685 Recent Advances of Vaccine Adjuvants for Infectious Diseases Sujin Lee1,2* and Minh Trang Nguyen1,2 1Department of Pediatrics, Emory University, School of Medicine, 2Children's Healthcare of Atlanta, Atlanta, Georgia 30322, USA Vaccines are the most effective and cost-efficient method for VACCINES preventing diseases caused by infectious pathogens. Despite the great success of vaccines, development of safe Infectious diseases remain the second leading cause of death and strong vaccines is still required for emerging new patho- worldwide after cardiovascular disease, but the leading cause gens, re-emerging old pathogens, and in order to improve the of death in infants and children (1). Vaccination is the most inadequate protection conferred by existing vaccines. One of efficient tool for preventing a variety of infectious diseases. the most important strategies for the development of effec- The ultimate goal of vaccination is to generate a patho- tive new vaccines is the selection and usage of a suitable adjuvant. Immunologic adjuvants are essential for enhancing gen-specific immune response providing long-lasting pro- vaccine potency by improvement of the humoral and/or tection against infection (2). Despite the significant success cell-mediated immune response to vaccine antigens. Thus, of vaccines, development of safe and strong vaccines is still formulation of vaccines with appropriate adjuvants is an at- required due to the emergence of new pathogens, re-emer- tractive approach towards eliciting protective and long-last- gence of old pathogens and suboptimal protection conferred ing immunity in humans. However, only a limited number of by existing vaccines. Recent important emerging or re-emerg- adjuvants is licensed for human vaccines due to concerns ing diseases were severe acute respiratory syndrome (SARS) about safety and toxicity. We summarize current knowledge in 2003, the 2009 H1N1 influenza pandemic, and Ebola virus about the potential benefits of adjuvants, the characteristics in 2014 (3). Last year, the most widespread epidemic of Ebola of adjuvants and the mechanisms of adjuvants in human virus caused significant mortality in several West African vaccines. Adjuvants have diverse modes of action and should countries (4). As a result, we are aware of pursuing a new be selected for use on the basis of the type of immune re- approach towards the rapid development of vaccines against sponse that is desired for a particular vaccine. Better under- standing of current adjuvants will help exploring new ad- emerging diseases. juvant formulations and facilitate rational design of vaccines Three different types of vaccine are currently used in hu- against infectious diseases. mans: live-attenuated vaccines, inactivated vaccines and sub- [Immune Network 2015;15(2):51-57] unit vaccines (5). Many of the most effective vaccines in use are live-attenuated vaccines. As an attenuated vaccine is com- Keywords: Vaccine, Adjuvant, Infectious disease, Innate im- posed of a virus or bacterium that can replicate within the munity, Adaptive immunity host, this type of vaccine elicits robust humoral and cell-medi- ated immunity (CMI). Examples of live-attenuated vaccine in- clude MMR (Measles, Mumps, Rubella), chicken pox, oral po- lio (Sabin), influenza (the seasonal flu nasal spray and the Received on February 10, 2015. Revised on March 28, 2015. Accepted on April 2, 2015. CC This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribu- tion, and reproduction in any medium, provided the original work is properly cited. *Corresponding Author. Sujin Lee, Department of Pediatrics, Emory Children’s Center, Emory University, 2015 Uppergate Dr. NE Rm 512, Atlanta, GA 30322, United States of America. Tel: 404-712-1637; Fax: 404-727-9223; E-mail: [email protected] Abbreviations: CMI, cell-mediated immunity; DC, dendritic cell; IRIV, immunopotentiating reconstituted influenza viro- somes; PRR, pattern recognition receptors; ODN, oligodeoxynucleotides; poly I:C, polyriboinosinic acid-polyribocytidylic acid; ISCOM, immune stimulating complexes IMMUNE NETWORK Vol. 15, No. 2: 51-57, April, 2015 51 Recent Advances of Vaccine Adjuvants for Infectious Diseases Sujin Lee and Minh Trang Nguyen 2009 H1N1 nasal spray), rotavirus and yellow fever vaccine. because it is a poor inducer of T cell responses. The use of Inactivated (killed) vaccines (e.g. inactivated polio - Salk, appropriate adjuvants will allow for vaccine formulations that Hepatitis A) are either heat-inactivated or chemically in- selectively trigger innate immunity and/or adaptive immunity activated particles of the pathogen. Although these vaccines to obtain a desired type of antigen-specific immune are safe and non-infectious, they stimulate only weak, responses. We also describe the practical and functional rea- short-lived and often insufficient immunity. Thus, large and sons for why adjuvants are needed as a component in vac- multiple doses of inactivated vaccine are required to confer cines in Table I. protective immunity (6). In contrast to live-attenuated vac- cines, inactivated vaccines elicit mainly humoral immunity, ADJUVANTS APPROVED FOR HUMAN VACCINES with little to no induction of CMI. Purified or recombinant subunit vaccines derived from Licensed adjuvants in use for human vaccines are listed in non-living vaccine antigens are poorly immunogenic and re- Table II. quire the addition of some components to help stimulate pro- tective immunity. In some cases, these vaccines utilize epito- Aluminium Salts (Alum) pes recognized and bound by antibodies or T-cells. Because In 1926, Glenny et al. reported the adjuvant activity of alumi- subunit vaccines contain only an essential part of the antigen nium compounds utilizing a suspension of alum-precipitated instead of the entire microbe, the chances of adverse re- diphtheria toxoid (DT) (8). Aluminium salts are the most actions to the vaccine are relatively low (7). Subunit vaccines widely used adjuvants in human vaccines. These adjuvants have been made for hepatitis B virus (HBV), influenza virus have been used in practical vaccination for more than 80 (injection) and pertussis (part of DTaP combined immuniza- years and are generally considered stimulators of Th2 im- tion). Recently developed subunit vaccines are less immuno- munity (9,10). Until 2009 aluminium salt (referred to as genic and reactogenic than traditional vaccines such as live-at- “alum”) adjuvants were the only ones contained in vaccines tenuated, and inactivated vaccines. Thus, repeated boost im- licensed for human use in the United States. Alum is a com- munizations or the addition of adjuvant are necessary to en- ponent of licensed human vaccines such as Hepatitis A virus hance the efficacy of subunit vaccines. (HAV), Hepatitis B virus (HBV), human papilloma virus (HPV), diphtheria, tetanus, Haemophilus Influenzae Type b NEED FOR ADJUVANTS (Hib) and meningococcal. Although there are a number of adjuvants more potent than alum, they have not been used The word “adjuvant” is derived from the Latin adjuvare, for human vaccine formulations due to high levels of toxicity. meaning “to help” or “to aid”. Adjuvants have been defined Surprisingly, despite the wide use of alum adjuvants in li- as agents added to vaccine formulations that enhance the im- censed human vaccines, the mechanisms of action are not munogenicity of antigens and induce protection against well characterized. The most well-known mechanism of ac- infection. Vaccines made from live-attenuated or inactivated tion of alum is the “depot effect”, first proposed by Glenny pathogens can elicit robust protective immune responses be- in 1925, whereby depot formation was cited to facilitate con- cause those vaccines contain naturally occurring adjuvants. In contrast, protein-based vaccines in most cases have limited Table I. The benefits of adjuvants immunogenicity although they have some advantages in terms of safety and cost-effectiveness. Thus, adjuvants are 1. Decrease the dose of antigen needed (dose sparing) necessary to help these proteins become effective vaccines 2. Decrease the number of vaccine doses needed by inducing strong and long-lasting protective immune 3. Enhance vaccine efficacy in infants, the elderly and immunocompromised people responses. Indeed, some protein-based vaccines have been 4. Increase functional antibody titer successfully developed in use for human vaccines by mixing 5. Induce more rapid and long-lasting immune responses with aluminium salts (alum). However, new vaccine targets 6. Induce robust cell-mediated immunity will require not only strong antibody responses but also ro- 7. Provide broad protection (cross-reactivity) bust CMI including T helper (Th) cells and cytotoxic T lym- 8. Facilitate mucosal immunity phocytes (CTL). Alum alone will be insufficient for such cases 9. Overcome antigen competition in combination vaccines 52 IMMUNE NETWORK Vol. 15, No. 2: 51-57, April, 2015 Recent Advances of Vaccine Adjuvants for Infectious Diseases Sujin Lee and Minh Trang Nguyen Table II. Licensed vaccine adjuvants Adjuvant name Class Manufacturer Description References (year licensed) Alum (1926) Mineral Salt Various Improves humoral immune responses and antigen stability. (44, 45) Antigens are adsorbed to the surface. The adjuvant
Recommended publications
  • 1 Title: Interim Report of a Phase 2 Randomized Trial of a Plant
    medRxiv preprint doi: https://doi.org/10.1101/2021.05.14.21257248; this version posted May 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Title: Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle 2 Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older 3 Authors: Philipe Gobeil1, Stéphane Pillet1, Annie Séguin1, Iohann Boulay1, Asif Mahmood1, 4 Donald C Vinh 2, Nathalie Charland1, Philippe Boutet3, François Roman3, Robbert Van Der 5 Most4, Maria de los Angeles Ceregido Perez3, Brian J Ward1,2†, Nathalie Landry1† 6 Affiliations: 1 Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 7 3V9; 2 Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, 8 QC H4A 3J1; 3 GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre, 9 Belgium; 4 GlaxoSmithKline Biologicals SA (Vaccines), rue de l’Institut 89, 1330 Rixensart, 10 Belgium; † These individuals are equally credited as senior authors. 11 * Corresponding author: Nathalie Landry, 1020 Route de l’Église, Bureau 600, Québec, Qc, 12 Canada, G1V 3V9; Tel. 418 658 9393; Fax. 418 658 6699; [email protected] 13 Abstract 14 The rapid spread of SARS-CoV-2 globally continues to impact humanity on a global scale with 15 rising morbidity and mortality. Despite the development of multiple effective vaccines, new 16 vaccines continue to be required to supply ongoing demand.
    [Show full text]
  • Curriculum Vitae
    CURRICULUM VITAE RINO RAPPUOLI Business address GSK Vaccines Via Fiorentina, 1 53100 Siena – ITALY Office: +39-0577-243414 Email: [email protected] Current positions 2015 - to date Chief Scientist and Head External R&D, GlaxoSmithKline Vaccines (Siena, Italy). Previous positions 2017 - 2019 Professor of Vaccines Research, Faculty of Medicine, Imperial College (London, United Kingdom) 2014 Global Head Research and Development, Novartis Vaccines (Siena, Italy). 2007-2015 Founder and chairman of the Board of the Novartis Vaccines Institute for Global Health (Siena, Italy). 2006 Global Head Vaccines Research, Novartis Vaccines & Diagnostics (Siena, Italy). 2003 Chief Scientific Officer and Vice President Vaccines Research, Chiron Corporation (Emeryville, USA). 1996 Vice President Vaccines Research, Chiron Corporation (Emeryville, USA). 1992 Head of Research of IRIS, the Chiron S.p.A. Research Institute (Siena, Italy). 1988-1991 Head of the Sclavo Research and Development (Siena, Italy). 1985-1987 Head of the laboratory of Bacterial Vaccines at the Sclavo Research Center. Worked on the molecular genetics of Bordetella pertussis and the development of a new vaccine against whooping cough. 1982-1984 Sclavo Research Center, Worked on the molecular biology of Corynebacterium diphtheriae and the development of a new vaccine against diphtheria. 1980-1981 Visiting scientist at the Harvard Medical School (Boston, USA). Worked on the molecular biology of bacteriophages of Corynebacterium diphtheriae in the laboratory of John Murphy. 1979 Visiting scientist for four months at the Rockefeller University (New York, USA). Worked on the purification of gonococcal antigens in the laboratory of Emil Gotschlich. 1978-1984 Staff scientist at the Sclavo Research Center (Siena, Italy).
    [Show full text]
  • Systems Biology of Immunity to MF59-Adjuvanted Versus
    Systems biology of immunity to MF59-adjuvanted SEE COMMENTARY versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood Helder I. Nakayaa,b,1, Elizabeth Clutterbuckc,1, Dmitri Kazmind,1, Lili Wange,1, Mario Cortesed, Steven E. Bosingerd,f, Nirav B. Patelf, Daniel E. Zakg, Alan Aderemg, Tao Donge, Giuseppe Del Giudiceh, Rino Rappuolih,2, Vincenzo Cerundoloe, Andrew J. Pollardc, Bali Pulendranb,d,2, and Claire-Anne Siegristi,2 aDepartment of Pathophysiology and Toxicology, School of Pharmaceutical Sciences, University of São Paulo, 05508, São Paulo, Brazil; bDepartment of Pathology, Emory University School of Medicine, Atlanta, GA 30322; cOxford Vaccine Group, Department of Pediatrics, University of Oxford and the National Institute for Health Research Oxford Biomedical Research Centre, Oxford OX3 9DU, United Kingdom; dEmory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30329; eMedical Research Council Human Immunology Unit, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DU, United Kingdom; fDivision of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, GA 30322; gCenter for Infectious Disease Research, Seattle, WA 98109; hResearch Center, Novartis Vaccines, 53100 Siena, Italy; and iWHO Collaborative Center for Vaccine Immunology, Departments of Pathology-Immunology and Pediatrics, University of Geneva, 1211 Geneva, Switzerland Contributed by Rino Rappuoli, November 24, 2015 (sent for review April 29, 2015; reviewed by Adolfo Garcia-Sastre, Stefan H. E. Kaufmann, and Federica Sallusto) The dynamics and molecular mechanisms underlying vaccine immu- administered to over 5,000 children in clinical trials (11) and nity in early childhood remain poorly understood. Here we applied showed enhanced immunogenicity and efficacy compared with TIV systems approaches to investigate the innate and adaptive re- (2).
    [Show full text]
  • Product Information for Pandemrix H1N1 Pandemic Influenza Vaccine
    Attachment 1: Product information for Pandemrix H1N1 pandemic influenza vaccine. Influenza virus haemagglutinin (A/California/7/2009(H1N1)v-like strain). GlaxoSmithKline Australia Pty Ltd. PM-2010- 02995-3-2 Final 12 February 2013. This Product Information was approved at the time this AusPAR was published. PANDEMRIX™ H1N1 PRODUCT INFORMATION Pandemic influenza vaccine (split virion, inactivated, AS03 adjuvanted) NAME OF THE MEDICINE PANDEMRIX H1N1, emulsion and suspension for emulsion for injection. Pandemic influenza vaccine (split virion, inactivated, AS03 adjuvanted). DESCRIPTION Each 0.5mL vaccine dose contains 3.75 micrograms1 of antigen2 of A/California/7/2009 (H1N1)v- like strain and is adjuvanted with AS033. 1haemagglutinin 2propagated in eggs 3The GlaxoSmithKline proprietary AS03 adjuvant system is composed of squalene (10.68 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.85 milligrams) This vaccine complies with the World Health Organisation (WHO) recommendation for the pandemic. Each 0.5mL vaccine dose also contains the excipients Polysorbate 80, Octoxinol 10, Thiomersal, Sodium Chloride, Disodium hydrogen phosphate, Potassium dihydrogen phosphate, Potassium Chloride and Magnesium chloride. The vaccine may also contain the following residues: egg residues including ovalbumin, gentamicin sulfate, formaldehyde, sucrose and sodium deoxycholate. CLINICAL TRIALS This section describes the clinical experience with PANDEMRIX H1N1 after a single dose in healthy adults aged 18 years and older and the mock-up vaccines (Pandemrix H5N1) following a two-dose administration. Mock-up vaccines contain influenza antigens that are different from those in the currently circulating influenza viruses. These antigens can be considered as “novel” antigens and simulate a situation where the target population for vaccination is immunologically naïve.
    [Show full text]
  • Public Assessment Report
    EMA/639703/2010 Committee for Medicinal Products for Human Use (CHMP) Assessment Report AFLUNOV Common Name: Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Procedure No. EMEA/H/C/002094 Assessment Report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7523 7455 E-mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2010. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents......................................................................................... 2 1. Background information on the procedure .............................................. 3 1.1. Submission of the dossier.................................................................................... 3 1.2. Steps taken for the assessment of the product ....................................................... 4 2. Scientific discussion ................................................................................ 5 2.1. Introduction ...................................................................................................... 5 2.2. Quality aspects .................................................................................................. 6 2.2.1. Introduction ................................................................................................... 6 2.2.2.
    [Show full text]
  • Enhanced Immune Response After a Second Dose of an AS03-Adjuvanted H1N1 Influenza a Vaccine in Patients After Hematopoietic Stem Cell Transplantation
    BRIEF ARTICLES Enhanced Immune Response after a Second Dose of an AS03-Adjuvanted H1N1 Influenza A Vaccine in Patients after Hematopoietic Stem Cell Transplantation Saskia Gueller,1 Regina Allwinn,2 Sabine Mousset,1 Hans Martin,1 Imke Wieters,4 Eva Herrmann,3 Hubert Serve,1 Markus Bickel,4,* Gesine Bug1,* Seroconversion rates following influenza vaccination in patients with hematologic malignancies after hema- topoietic stem cell transplantation (HSCT) are known to be lower compared to healthy adults. The aim of our diagnostic study was to determine the rate of seroconversion after 1 or 2 doses of a novel split virion, inactivated, AS03-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HSCT recipients (ClinicalTrials.gov Identifier: NCT01017172). Blood samples were taken before and 21 days after a first dose and 21 days after a second dose of the vaccine. Antibody (AB) titers were determined by hemaggluti- nation inhibition assay. Seroconversion was defined by either an AB titer of #1:10 before and $1:40 after or $1:10 before and $4-fold increase in AB titer 21 days after vaccination. Seventeen patients (14 allogeneic, 3 autologous HSCT) received 1 dose and 11 of these patients 2 doses of the vaccine. The rate of seroconver- sion was 41.2% (95% confidence interval [CI] 18.4-67.1) after the first and 81.8% (95% CI 48.2-97.7) after the second dose. Patients who failed to seroconvert after 1 dose of the vaccine were more likely to receive any immunosuppressive agent (P 5 .003), but time elapsed after or type of HSCT, age, sex, or chronic graft- versus-host disease was not different when compared to patients with seroconversion.
    [Show full text]
  • Immunological Considerations for COVID-19 Vaccine Strategies
    REVIEWS Immunological considerations for COVID-19 vaccine strategies Mangalakumari Jeyanathan1,2,3,5, Sam Afkhami1,2,3,5, Fiona Smaill2,3, Matthew S. Miller1,3,4, Brian D. Lichty 1,2 ✉ and Zhou Xing 1,2,3 ✉ Abstract | The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) is the most formidable challenge to humanity in a century. It is widely believed that prepandemic normalcy will never return until a safe and effective vaccine strategy becomes available and a global vaccination programme is implemented successfully. Here, we discuss the immunological principles that need to be taken into consideration in the development of COVID-19 vaccine strategies. On the basis of these principles, we examine the current COVID-19 vaccine candidates, their strengths and potential shortfalls, and make inferences about their chances of success. Finally, we discuss the scientific and practical challenges that will be faced in the process of developing a successful vaccine and the ways in which COVID-19 vaccine strategies may evolve over the next few years. The coronavirus disease 2019 (COVID-19) outbreak constitute a safe and immunologically effective COVID-19 was first reported in Wuhan, China, in late 2019 and, at vaccine strategy, how to define successful end points the time of writing this article, has since spread to 216 in vaccine efficacy testing and what to expect from countries and territories1. It has brought the world to a the global vaccine effort over the next few years. This standstill. The respiratory viral pathogen severe acute Review outlines the guiding immunological principles respiratory syndrome coronavirus 2 (SARS-CoV-2) has for the design of COVID-19 vaccine strategies and anal- infected at least 20.1 million individuals and killed more yses the current COVID-19 vaccine landscape and the than 737,000 people globally, and counting1.
    [Show full text]
  • Key Roles of Adjuvants in Modern Vaccines
    R E V I E W Key roles of adjuvants in modern vaccines Steven G Reed, Mark T Orr & Christopher B Fox Vaccines containing novel adjuvant formulations are increasingly reaching advanced development and licensing stages, providing new tools to fill previously unmet clinical needs. However, many adjuvants fail during product development owing to factors such as manufacturability, stability, lack of effectiveness, unacceptable levels of tolerability or safety concerns. This Review outlines the potential benefits of adjuvants in current and future vaccines and describes the importance of formulation and mechanisms of action of adjuvants. Moreover, we emphasize safety considerations and other crucial aspects in the clinical development of effective adjuvants that will help facilitate effective next-generation vaccines against devastating infectious diseases. Adjuvants have proven to be key components in vaccines that are Modern adjuvant development, which in spite of many hurdles is today taken for granted. Indeed, many vaccines, comprised of whole or progressing, is based on enhancing and shaping vaccine-induced killed bacteria or viruses, have inherent immune-potentiating activity. responses without compromising safety by selectively adding well- However, attempts to develop a new generation of adjuvants, which defined molecules, formulations or both. Because vaccines are often will be essential for new vaccines, have been hindered somewhat by employed prophylactically in populations of very young people, it perceived, but most often undocumented, health risks and public is important that medical risks to the subject (that is, safety) and misinformation, rather than by verified safety issues. Nonetheless, it other adverse effects (that is, tolerability) are addressed. Vaccine is essential that vaccine and adjuvant developers fully utilize infor- adjuvants designed for therapeutic uses, such as in cancer, may mation on adjuvants’ modes of action, avoid using undefined com- have a different risk-benefit profile.
    [Show full text]
  • Pumarix, INN-Pandemic Influenza Vaccine (H5N1)
    authorised ANNEX I SUMMARY OF PRODUCT CHARACTERISTICSlonger no product Medicinal 1 1. NAME OF THE MEDICINAL PRODUCT Pumarix suspension and emulsion for emulsion for injection Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen* equivalent to: A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2) 3.75 micrograms** * propagated in eggs ** haemagglutinin This vaccine complies with the WHO recommendation and EU decision for the pandemic. AS03 adjuvant composed of squalene (10.69 milligrams), DL-α-tocopherol (11.86authorised milligrams) and polysorbate 80 (4.86 milligrams) The suspension and emulsion, once mixed, form a multidose vaccine in a vial. See section 6.5 for the number of doses per vial. Excipient with known effect: the vaccine contains 5 microgramslonger thiomersal For the full list of excipients see section 6.1. no 3. PHARMACEUTICAL FORM Suspension and emulsion for emulsion for injection. The suspension is a translucent to off white opalescent suspension, which may sediment slightly. The emulsion is a whitish homogeneous liquid. 4. CLINICAL PARTICULARSproduct 4.1 Therapeutic indications Prophylaxis of influenza in an officially declared pandemic situation (see sections 4.2 and 5.1). Pandemic influenza vaccine should be used in accordance with official guidance. 4.2 Posology and method of administration MedicinalPosology Adults from the age of 18 years onwards: One dose of 0.5 ml at an elected date. A second dose of 0.5 ml should be given after an interval of at least three weeks. 2 Persons previously vaccinated with one or two doses of AS03-containing vaccine containing HA derived from a different clade of the same subtype Adults from the age of 18 years onwards: one dose of 0.5 ml at an elected date.
    [Show full text]
  • Pandemrix, INN-Influenza Vaccine (H1N1)V (Split Virion, Inactivated, Adjuvanted)
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Pandemrix suspension and emulsion for emulsion for injection. Influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION After mixing, 1 dose (0.5 ml) contains: Split influenza virus, inactivated, containing antigen* equivalent to: A/California/07/2009 (H1N1) derived strain used NYMC X-179A 3.75 micrograms** * propagated in eggs ** haemagglutinin AS03 adjuvant composed of squalene (10.69 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.86 milligrams) The suspension and emulsion, once mixed, form a multidose vaccine in a vial. See section 6.5 for the number of doses per vial. Excipient with known effect The vaccine contains 5 micrograms thiomersal For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension and emulsion for emulsion for injection. The suspension is a colourless light opalescent liquid. The emulsion is a whitish to yellowish homogeneous milky liquid. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Prophylaxis of influenza caused by A (H1N1)v 2009 virus. Pandemrix should only be used if the recommended annual seasonal trivalent/quadrivalent influenza vaccines are not available and if immunisation against (H1N1)v is considered necessary (see sections 4.4 and 4.8). Pandemrix should be used in accordance with Official Guidance. 4.2 Posology and method of administration Posology 2 The dose recommendations take into account the safety and immunogenicity data from clinical studies in healthy subjects See sections 4.4, 4.8 and 5.1 for details.
    [Show full text]
  • Challenges in Confronting Pandemic Influenza Using Novel Adjuvanted Vaccines
    Challenges in Confronting Pandemic Influenza Using Novel Adjuvanted Vaccines 1 Pandemic Influenza • Epidemiologic characteristics: • High attack rates across broad age ranges • Rapid geographic spread • Variable mortality (but low as many plagues go) • Extremes of age and pregnancy impose high risk • Fatal disease predominantly pulmonary • Short, explosive outbreaks in populous areas, that may recur in “waves” • Virologic characteristics: • Causative viruses with which a large proportion of the human population then-living has no immunologic experience • Persons old enough to have experienced pandemic subtypes earlier in life often spared. • Pandemic viruses often (not always) displace older subtypes 2 Origin of Pandemic Influenza Viruses • 16 HA subtypes and 9 NA subtypes harbored by aquatic birds • 3 HA subtypes and 2 NA subtypes have become stably endemic in humans • Known sources of pandemics include • Direct invasion of an avian virus (1918), • Return of an old HA subtype by re-assortment when enough humans are susceptible (?1957, 1968, now 2009) 3 Amplitude of the Pandemic Threat and Control Measures • Mortality may be massive, but not all pandemics are horrific: • 1918 “Spanish” flu – 40 to 50 M deaths • 1957 “Asian” flu – 1 to 2 M deaths • 1968 “Hong Kong” flu – 1 M deaths • 1977 “Lab accident flu” – little excess mortality • Our array of control measures is now greater: • Social distancing and non-pharmaceutical control measures were available in 1918, but better understood now • Anti-virals are new on the scene • Potential for rapid evolution of resistance • Vaccines 4 Waves of Pandemic Virus Transmission and Disease UK, 1918-19 7 months March April May Mortality spikes in 30 of 50 largest US cities, influenza in France Outbreaks at multiple US Army camps Severe influenza in Haskell County KS Tauenberger JK, Morens DM.
    [Show full text]
  • (H5N1), AS03 Adjuvanted
    Australian Public Assessment Report for purified antigen fractions of inactivated split virion A/Indonesia/05/2005 (H5N1), AS03 adjuvanted Proprietary Product Name: Prepandrix Sponsor: GlaxoSmithKline Australia Pty Ltd December 2015 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision‐ making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time.
    [Show full text]